Cover Image
市場調查報告書

淋巴球活化基因3蛋白:開發中產品分析

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 367843
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
淋巴球活化基因3蛋白:開發中產品分析 Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H2 2016
出版日期: 2016年07月27日 內容資訊: 英文 51 Pages
簡介

本報告提供以淋巴球活化基因3蛋白(LAG-3)為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

淋巴球活化基因3蛋白(LAG-3) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥開發企業

  • Bristol-Myers Squibb Company
  • Enumeral Biomedical Holdings, Inc.
  • GlaxoSmithKline Plc
  • Incyte Corporation
  • MacroGenics, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Sutro Biopharma, Inc.
  • Symphogen A/S
  • Tesaro, Inc.

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0417TDB

Summary

Global Markets Direct's, 'Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H2 2016', provides in depth analysis on Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted pipeline therapeutics.

The report provides comprehensive information on the Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
  • The report reviews Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) Overview
    • Therapeutics Development
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Products under Development by Stage of Development
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Products under Development by Therapy Area
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Products under Development by Indication
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Products under Development by Companies
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Companies Involved in Therapeutics Development
    • Bristol-Myers Squibb Company
    • Enumeral Biomedical Holdings, Inc.
    • GlaxoSmithKline Plc
    • Incyte Corporation
    • MacroGenics, Inc.
    • Novartis AG
    • Regeneron Pharmaceuticals, Inc.
    • Sutro Biopharma, Inc.
    • Symphogen A/S
    • Tesaro, Inc.
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Drug Profiles
    • BMS-986016 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ENUM-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2831781 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMP-701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMP-731 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LAG-525 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MGD-013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit LAG-3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit LAG-3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit LAG3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit LAG3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit PD-1 and LAG3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Replace CD223 for Cardiovascular Disease and Chronic Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TSR-033 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Dormant Projects
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Featured News & Press Releases
    • Apr 19, 2016: MacroGenics Presents Data from MGD013 Preclinical Program at AACR Annual Meeting 2016
    • Jan 27, 2016: US Patent Grants for IMP731 Antibody
    • Aug 14, 2015: Prima Biomed Announces Commencement of Milestones for IMP701 Program
    • Jan 28, 2015: Prima BioMed to Receive Financial Milestone Payment From GSK
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Pipeline by Enumeral Biomedical Holdings, Inc., H2 2016
  • Pipeline by GlaxoSmithKline Plc, H2 2016
  • Pipeline by Incyte Corporation, H2 2016
  • Pipeline by MacroGenics, Inc., H2 2016
  • Pipeline by Novartis AG, H2 2016
  • Pipeline by Regeneron Pharmaceuticals, Inc., H2 2016
  • Pipeline by Sutro Biopharma, Inc., H2 2016
  • Pipeline by Symphogen A/S, H2 2016
  • Pipeline by Tesaro, Inc., H2 2016
  • Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top